Hospital leaders are concerned about how to get ready to take on more risk, said Tim Gronniger, MPP, MHSA, senior vice president of development and strategy at Caravan Health.
Hospital leaders are concerned about how to get ready to take on more risk, said Tim Gronniger, MPP, MHSA, senior vice president of development and strategy at Caravan Health.
Transcript
When working with hospital leaders, how do you discuss the future of ACOs in the United States?
That’s a big question. We talk about a lot of different things with our clients, and the reading we’re getting from Washington, very clearly, is that Medicare wants ACOS to take risk. So, a lot of our discussions lately have been around, how do you get ready for that world? What sort of systems and competencies do you need to put in place? What does your staffing model need to look like? What do you need to do to work more effectively with your physicians, and like we talked about a little bit earlier this morning, what do you need to do to make sure your large enough to be able to take risk effectively?
What concerns are top of mind for the providers and hospital systems that you work with?
There’s the joke that every health system CEO has a to-do list that’s about a hundred items long, and they only get to the first 10 on the list. So, at any given day in my world, they’re worrying about what’s going to be happening with CMS policy. They’re worrying about what’s happening with their staff. They’re worrying about what their performance is over the last month and over the last quarter on metrics that we track, and they’re always planning for the next year as well. So, the initial work in our model is geared around getting ready to put in place practices, build up primary care capacity, and get hired and trained the right kind of nursing support to deliver effective preventive and primary care, and then, to track performance on metrics that will determine success in the AC over time.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More